ObjectiveTo construct a nomogram prediction model for pain crisis occurrence based on clinical data of patients with advanced non-small cell lung cancer (NSCLC), with the aim of providing a scientific basis for clinical decision-making.MethodsA total of patients with advanced non-small cell lung cancer (NSCLC) admitted to our hospital from January 2022 to January 2024 were selected as the study subjects. Demographic data, disease information, pain severity (assessed using the Numerical Rating Scale, NRS), psychological status (anxiety and depression assessed using the Self-Rating Anxiety Scale, SAS, and the Self-Rating Depression Scale, SDS), and social support (assessed using the Perceived Social Support Scale, PSSS) were collected. Univariate and multivariate Logistic regression analyses were performed to identify independent factors influencing pain crisis. The R software was used to visualize the nomogram, and the Receiver Operating Characteristic (ROC) curve, calibration curve, and Hosmer-Lemeshow test were employed to evaluate the discrimination and calibration of the model.ResultsA total of 500 questionnaires were distributed, and 448 qualified questionnaires were collected, with a qualification rate of 89.6%. The patients were divided into a modeling group (n=314) and a validation group (n=134). Univariate analysis showed significant differences between the pain crisis group and the pain-free group in terms of gender, age, education level, PSSS score, bone metastases, pleural metastases, depression and anxiety levels, and antitumor efficacy (P<0.05). Multivariate Logistic regression analysis showed that bone metastasis, PSSS score, age, depression, and anxiety levels were independent factors influencing pain crisis in patients with advanced NSCLC. Based on the results of the multivariate Logistic regression analysis, a nomogram prediction model for pain crisis occurrence in patients with advanced NSCLC was constructed. The Area Under the Curve (AUC) of the ROC curve in the modeling and validation groups was 0.948 and 0.921, respectively, indicating high discrimination of the model. The calibration curve and Hosmer-Lemeshow test results showed good consistency of the model.ConclusionThis study successfully constructed and validated a nomogram prediction model based on independent factors such as bone metastasis, social support (PSSS score), age, depression, and anxiety levels. This model can objectively and quantitatively predict the risk of pain crisis occurrence in patients with advanced NSCLC, providing a scientific basis for clinical decision-making. It helps identify high-risk patients with pain crisis in advance and optimize pain management strategies, thereby improving patient prognosis and quality of life.
Objective To investigate the association between types of rapid eye movements during sleep and ICD-10 as a mothod for diagnosing depression. Methods Depression was diagnosed according to ICD-10 and changes of 9 variables of REM sleep in 120 psychiatric outpatients and inpatients by calculating the Kappa values. Results In 120 psychiatric patients, 52 depressive patients were diagnosed by using ICD-10, and 58 patients were diagnosed as depression according to decreased REM sleep latency and increased REM activity, REM intensity, REM density, and increasing amount of REM sleep. Kappa value was 0.73, Plt;0.05, which implied that these two diagnosing ways were significantly consistent. Conclusions Measuremen of REM sleep variable should be investigated further as a supplementary method for diagnosing depression.
ObjectiveTo explore the association between paroxetine (Seroxat) and level of blood sugar and endocrine hormones in pre-diabetes patients with anxiety and depression. MethodsFifty-four pre-diabetes patients with anxiety and depression diagnosed from January 2010 to December 2012 were recruited. The self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were used to assess depression and anxiety. All the patients were treated by paroxetine. The glucose tolerance test (OGTT), ACTH and cortisol were tested in patients at baseline and within 24 weeks. ResultsAfter 24 weeks' treatment, the level of anxiety and depression as well as the OGTT 0.5 h (0.5 h PG), OGTT 1 h (1 h PG), OGTT 2 h (2 h PG), glycated hemoglobin (HbA1c), adrenocorticotropic hormone (ACTH) and cortisol were significantly decreased (P<0.05 or P<0.01). The glycated HbA1c had a positive correlation with adrenocorticotropic hormone (ACTH) and cortisol (F). Before and after treatment, the reduced rate of ACTH and reduced rate of cortisol respectively exhibited a positive correlation with the reduced rate of HbA1c, reduced rate of SAS and reduced rate of SDS. ConclusionAnti-anxiety depression treatment can lower blood sugar level in pre-diabetes patients with anxiety and depression significantly, which may be related to the activity of HPA axis.
ObjectiveTo compare the anxiety, depressive and personality characteristics between diabetes mellitus patients with or without diabetic retinopathy (DR), and look for psychological treatment and corresponding prevention measures. Methods435 diabetic patients were enrolled in this study from April to November 2014 in our hospital, including 178 DR cases (group A) and 257 cases without retinopathy (group B). All the patients completed a questionnaire, the Self-Rating Anxiety (SAS), the Self-Rating Depression Scale (SDS) and the big five personality scale (NEO-FFI), and were scored by eye doctors. According to the score, SAS can be divided into mild anxiety, moderate anxiety, and severe anxiety. SDS is divided into depression, mild depression, moderate depression and major depression. NEO-FFI was scored from emotional stability, outgoing, openness, easy-going and sense of responsibility. Multiple linear regression analysis was used to analyze the DR risk factors in those scores and education level, high blood pressure, age, alcohol consumption, occupation and other factors. ResultsThere were 110 cases of mild anxiety, 57 cases of moderate anxiety, 11 cases of severe anxiety; 74 cases without depression, 53 cases of mild depression, 31 cases of moderate depression, 20 cases with major depression in group A. There were 181 cases of mild anxiety, 53 cases of moderate anxiety, 23 cases of severe anxiety; 177 cases without depression, 44 cases of mild depression, 25 cases of moderate depression, 11 cases with major depression in group B. Group A patients had higher SAS, SDS scores than group B, the difference was statistically significant (P=0.035). Group B patients had higher NEO-FFI score in outgoing, easygoing, responsibility (P=0.022), lower NEO-FFI score in emotional stability (P=0.014) and same NEO-FFI score in openness(P=0.210)compare to Group A patients. Multiple linear regression analysis results showed that education level, high blood pressure, age, weight, drinking, occupation can affect the degree of changes in the retina (P=0.019). ConclusionsCompared with those without retinopathy, DR patients were more prone to anxiety and depression. They also had low score in personality characteristics of outgoing, easygoing, responsibility.
ObjectiveTo systematically review the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in the treatment of Parkinson's disease patients with depression. MethodsThe Cochrane Library (Issue 5, 2014), PubMed, EMbase, CNKI, VIP and WanFang Data databases were searched from inception to May 2014 for randomized controlled trials (RCTs) investigating the efficacy and safety of SSRIs for Parkinson's disease patients with depression. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. ResultsA total of 12 RCTs were included. The results of meta-analysis showed that the efficacy of SSRIs was better than placebo (RR=2.18, 95%CI 1.60 to 2.97, P<0.000 01) and the dropouts rates of SSRIs were higher than placebo (OR=3.02, 95%CI 1.04 to 8.79, P=0.04). However, the incidence rate of adverse events between the SSRIs group and the placebo group was not statistically different. ConclusionCurrent evidence indicates that SSRIs are effective for the Parkinson's disease patients with depression. Because of the limitation of quantity and quality of included studies, large-scale multi-center RCTs are required to confirm these findings.
ObjectiveTo evaluate the clinical efficacy of flupentixol and melitracen tablets on the treatment of chronic obstructive pulmonary disease (COPD) with anxiety and/or depression.MethodsRandomized controlled trials of flupentixol and melitracen tablets in the treatment of COPD with anxiety and/or depression were retrieved from PubMed, Sciencedirect Database, China National Knowledge Infrastructure, Wanfang Database, and CQVIP Journal Database, with retrieval time from January 2010 to December 2019. Two researchers screened literature and extracted data independently, and meta-analyzed the results using RevMan 5.3 software.ResultsA total of 9 articles with 1 123 patients were included. There were 567 patients in the trial group receiving flupentixol and melitracen tablets plus symptomatic support therapy and 556 patients in the control group receiving simple symptomatic treatment. After treatment, the Hamilton Anxiety Scale score [mean difference (MD)=−5.10, 95% confidence interval (CI) (−7.67, −2.54), P<0.000 1] and Hamilton Depression Scale score [MD=−3.94, 95%CI (−6.64, −1.23), P=0.004] in the trial group were lower than those in the control group, while the forced expiratory volume in one second as percentage of predicted volume [MD=4.89%, 95%CI (0.59%, 9.19%), P=0.03] and COPD Assessment Test score [MD=−3.21, 95%CI (−3.76, −2.66), P<0.000 01] in the trial group were better than those in the control group.ConclusionFlupentixol and melitracen tablets plus symptomatic support therapy has a better effect than simple symptomatic support treatment on COPD with anxiety and/or depression.
Objective To investigate the effect of music therapy plus selective serotonin reuptake inhibitors （SSRIs） on emotion and bum wound healing in bum patients. Methods Moderate and severe bum inpatient.s, aged 12-60 years were selected. Emotional problems were then measured by the Hamilton Rating Scale for Depression and Hamilton Rating Scale for Anxiety within three days after bum injury. Bum patients with depression and anxiety were randomly allocated into the trial group （28 patients） and the control group （27 patients）. Music therapy and SSRIs plus conventional burn care Were applied to the trial group, and conventional bum care to the control group, both for 30 days. The scores of anxiety, depression and the degree of bum wound healing were assessed. Results The differences of depression score and anxiety score before and after treatment were 13. 7 ±6.43 and 6.43 ±2.72 respectively in the trial group, and 4. 74 ±6.75 and 4.44 ±3.36 respectively in the control group. This showed both scores significantly improved compared with the control group （P 〈0. 05）. The time for burn wound healing was shortened in the treatment group （P 〈0. 05）. The anxiety score was positively correlated with bum index, and so was the depression score （P 〈 0.05 ）. Conclusions The anxiety and depression scores are positively correlated with the burn index. Music therapy plus SSrIs can ameliorate the emotional problems （ depression and anxiety）, and shorten the time for burn wound heating.
Evidence has been retrieved through MEDLINE and Cochrane Libray about the treatment for patients with advanced Parkinson’s disease who suffered from on-off, dyskinesia and depression after chronic use of L-dopa. All of the evidence has been evaluated. Methods of evidence-based treatment were drawn up according to the evidence, clinciams’ experiences and patients’ preferences. All symptoms of the patient have been improved obviously.
ObjectiveTo investigate the status of quality of life and influencing factors among newly diagnosed epilepsy patients with co-morbid anxiety and depression. MethodsA total of 180 newly diagnosed epilepsy patients from June 2022 to December 2022 in a district of Shanghai were selected as the study subjects. The Quality of Life in Epilepsy-31 (QOLIE-31), Hamilton Depression Rating Scale (HAMD-24), Hamilton Anxiety Rating Scale (HAMA), and Epilepsy Self-Management Scale (ESMS) were used to assess patients' quality of life, depression levels, anxiety levels, and self-management abilities, respectively. Patients were divided into the co-morbid depression group (HAMA≥14 and HAMD>17) and the control group (HAMA<14 and HAMD≤17), and their general characteristics and scale scores were compared. Spearman correlation, Pearson correlation, and multiple linear regression analysis were used to identify influencing factors of quality of life in epilepsy patients with co-morbid depression. ResultsCompared to the control group, the anxiety comorbid with depression group of older adults had a higher proportion, higher unemployment rate, lower personal and family annual income in the past year, higher frequency of epileptic seizures, and lower medication adherence (P<0.05). The correlational analysis revealed a negative correlation between the quality of life abilities of epilepsy patients with comorbid anxiety and depression and the severity of anxiety and depression. (r=−0.589, −0.620, P<0.05). The results of multiple linear regression analysis showed that the frequency of seizures in the past year (β=−1.379, P<0.05), severity of anxiety (β=−0.279, P<0.05), and severity of depression (β=−0.361, P<0.05) have an impact on the ability to quality of life in epilepsy patients with co-morbid anxiety and depression. These factors account for 44.1% of the total variability in quality of life (R2=0.4411, P<0.05). ConclusionThe frequency of seizures in the past year, as well as the severity of anxiety and depression, are important factors that influence the ability to quality of life in epilepsy patients with comorbid anxiety and depression. For these patients, it is crucial to take into account these factors and provide appropriate support and interventions.
The incidence of depression in patients with rheumatoid arthritis is higher. The concomitant depression will increase medical expense, reduce drug efficacy, lower its compliance, increase the incidence of complication, and affect the cure of rheumatoid arthritis. The influence of depression to rheumatoid arthritis is usually ignored in clinical work. In recent years, the pertinence between depression and immune disease in pathogenesis is found in research: depression will increase the risk of immune diseases in activate inflammation as well as extend and promote the release of inflammatory factors. This article reviews research progress of correlation between depression and rheumatoid arthritis.